Aurobindo Pharma has informed that in continuation to letter dated July 7, 2022, the 35th Annual General Meeting (AGM) of the Company was held on August 2, 2022 and the business mentioned in the AGM Notice dated June 17, 2022 was transacted. In this regard, it enclosed the following: Summary of proceedings as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Annexure-I, Voting Results as required under Regulation 44 of the SESI (Listing Obligations and Disclosure Requirements) Regulations 2015 as Annexure-II and The Report of Scrutinizer on remote e-voting and voting at AGM (by electronic means) as Annexure- III.
The above information is a part of company’s filings submitted to BSE.